Skip to main content

Advertisement

SpringerLink
Log in

Decision Making in Proliferative Diabetic Retinopathy Treatment

  • Retina (R Goldhardt, Section Editor)
  • Published:
Current Ophthalmology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The goal of this paper is to provide a comprehensive review of the recent advances in the management options for proliferative diabetic retinopathy.

Recent Findings

For many years, cases of proliferative diabetic retinopathy (PDR) have been managed by pan retinal photocoagulation (PRP). The advent of anti-vascular endothelial growth factor (anti-VEGF) agents has changed the future of PDR management and has provided an alternative to PRP.

Summary

Management of PDR requires the identification of high-risk characteristics for PDR and the decision regarding the most appropriate treatment modality. The risk to benefit ratio for each treatment modality must be considered in determining the appropriate choice between surgical intervention (PRP) versus medical intervention with anti-VEGF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Lee R, Wong T, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015;2:17.

    Article  Google Scholar 

  2. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of diabetic retinopathy study (DRS) findings, DRS report number 8. Ophthalmology. 1981;88(7):583–600.

    Article  Google Scholar 

  3. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227–39.

    Article  CAS  PubMed  Google Scholar 

  4. Ashton N. Studies of the retinal capillaries in relation to diabetic and other retinopathies. Br J Ophthalmol. 1963;47:521–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Cogan DG, Kuwabara T. Capillary shunts in the pathogenesis of diabetic retinopathy. Diabetes. 1963;12:293–300.

    Article  CAS  PubMed  Google Scholar 

  6. Cogan DG, Toussaint D, Kuwabara T. Retinal vascular patterns. IV. Diabetic retinopathy. Arch. Ophthalmol. 1961;66:366–78.

    Article  CAS  PubMed  Google Scholar 

  7. Kobayashi et al. Vitreous levels of vascular endothelial growth factor in eyes with anterior hyaloidal fibrovacular proliferation. Clin Ophthalmol. 2010;4:1043–6.

    Google Scholar 

  8. Gupta N, Mansoor S, Sharma A, Sapkal A, Sheth J, Falatoonzadeh P, et al. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013;7:4–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.

    Article  Google Scholar 

  10. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J. 1998;317(7160):703–13.

    Article  Google Scholar 

  11. Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol. 1976;81:383–96.

    Article  Google Scholar 

  12. Hamilton AM. Management of diabetic retinopathy. Trans Ophthalmol Soc UK. 1977;97:494–6.

    CAS  PubMed  Google Scholar 

  13. Hercules BL, Gayed II, Lucas SB, Jeacock J. Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three-year interim report of a randomised, controlled study using the argon laser. Br J Ophthalmol. 1977;61:555–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Meyers SM. Macular edema after scatter laser photocoagulation for proliferative diabetic retinopathy. Am J Ophthalmol. 1980;90:210–6.

    Article  CAS  PubMed  Google Scholar 

  15. Meyer-Schwickerath GRE, Schott K. Diabetic retinopathy and photocoagulation. Am J Ophthalmol. 1968;66:597–603.

    Article  CAS  PubMed  Google Scholar 

  16. Okun E, Cibis PA. The role of photocoagulation in the therapy of proliferative diabetic retinopathy. Arch Ophthalmol. 1966;75:337–52.

    Article  CAS  PubMed  Google Scholar 

  17. Patz A, Schatz H, Ryan SJ. Argon laser photocoagulation for treatment of advanced diabetic retinopathy. Trans Am Acad Ophthalmol Otolaryngol. 1972;76:984–9.

    CAS  PubMed  Google Scholar 

  18. Plumb AP, Swan AV, Chignell AH, Shilling JS. A comparative trial of xenon arc and argon laser photocoagulation in the treatment of proliferative diabetic retinopathy. Br J Ophthalmol. 1982;66:213–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98(5 suppl):766–85.

    Google Scholar 

  20. Mugit M, Marcellino G, Henson D, et al. Pascal panretinal laser and regression analysis in proliferative diabetic retinopathy: Manchester Pascal Study Report 4. Eye (Lond). 2011;25(11):1447–56.

    Article  Google Scholar 

  21. Mendrinos E, Mangioris G, Papadopoulou DN, et al. Retinal vessel analyzer measurements of the effect of panretinal photocoagulationon the retinal arteriolar diameter in diabetic retinopathy. Retina. 2010;30(4):555–61.

    Article  PubMed  Google Scholar 

  22. Funatsu H, Hori S, Yamashita H, Kitano S. Effective mechanisms of laser photocoagulation for neovascularization in diabetic retinopathy. Nippon Ganka Gakkai Zasshi. 1996;100(5):339–49.

    CAS  PubMed  Google Scholar 

  23. Marshall J, Clover G, Rothery S. Some new findings on retinal irradiation by krypton and argon lasers. Doc Ophthalmol Proc Ser. 1984;36:21–37.

    Google Scholar 

  24. Adamis AP, Miller JW, Bernal M-T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445–50.

    Article  CAS  PubMed  Google Scholar 

  25. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: EARLY Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103(12):1796–806.

    Article  Google Scholar 

  26. Brucker AJ, Qin H, Antoszyk AN, Diabetic Retinopathy Clinical Research Network, et al. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol. 2009;127(2):132–40.

    Article  PubMed  Google Scholar 

  27. Googe J, Brucker AJ, Bressler NM, Diabetic Retinopathy Clinical Research Network, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31(6):1009–27.

    Article  CAS  PubMed  Google Scholar 

  28. Berger AR, Boniuk I. Bilateral subretinal neovascularization after focal argon laser photocoagulation for diabetic macular edema. Am J Ophthalmol. 1989;108:88–90.

    Article  CAS  PubMed  Google Scholar 

  29. Lewis H, Schachat AP, Haimann MH. Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology. 1990;97:503–11.

    Article  CAS  PubMed  Google Scholar 

  30. Varley MP, Frank E, Purnell EW. Subretinal neovascularization after focal argon laser for diabetic macular edema. Ophthalmology. 1988;95:567–73.

    Article  CAS  PubMed  Google Scholar 

  31. Guyer DR, D’Amico DJ, Smith CW. Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol. 1992;113:652–6.

    Article  CAS  PubMed  Google Scholar 

  32. Han DP, Mieler WF, Burton TC. Submacular fibrosis after photocoagulation for diabetic macular edema. Am J Ophthalmol. 1992;113:513–21.

    Article  CAS  PubMed  Google Scholar 

  33. Rutledge BK, Wallow IHL, Poulsen GL. Sub-pigment epithelial membranes after photocoagulation for diabetic macular edema. Arch Ophthalmol. 1993;111:608–13.

    Article  CAS  PubMed  Google Scholar 

  34. Wallow IHL, Bindley CD. Focal photocoagulation of diabetic macular edema; a clinicopathologic case report. Retina. 1988;8:261–9.

    Article  CAS  PubMed  Google Scholar 

  35. Elliott A, Flanagan D. Macular detachment following laser treatment for proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 1990;228:438–41.

    Article  CAS  PubMed  Google Scholar 

  36. Schatz H, Madeira D, McDonald HR, Johnson RN. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol. 1991;109:1549–51.

    Article  CAS  PubMed  Google Scholar 

  37. Silva PS, Sun JK, Aiello LP. Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy. Semin Ophthalmol. 2009;24:93–9.

    Article  PubMed  Google Scholar 

  38. Zacks DN, Johnson MW. Combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation for concomitant diabetic macular edema and proliferative diabetic retinopathy. Retina. 2005;25:135–40.

    Article  PubMed  Google Scholar 

  39. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc. 1979;77:171–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Erdol H, Turk A, Akyol N, et al. The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy. Retina. 2010;30:570–7.

    Article  PubMed  Google Scholar 

  41. Yeh PT, Yang CM, Lin YC, et al. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina. 2009;29:768–74.

    Article  PubMed  Google Scholar 

  42. •• Writing Committee for the Diabetic Retinopathy Clinical Research Network. JAMA. 2015;314(20):2137–46 This study provides an in-depth comparison of the use of intravitreal ranibizumab vs PRP for the treatment of proliferative diabetic retinopathy.

    Article  CAS  Google Scholar 

  43. •• Gross JG, Glassman AR, Liu D, et al. Five-Year outcomes of panretinal photocoagulation vs intravitreal ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018. https://doi.org/10.1001/jamaophthalmol.2018.3255 This follow up study allowed the reader to observe how the primary outcome seen at 2 years was upheld, as well as allowed the observation of additional outcome measures regarding the use of intravitreal ranibizumab vs PRP for PDR.

  44. Gross JG, Glassman AR, Klein MJ, Jampol LM, Ferris FL III, Bressler NM, et al. Interim safety data comparing ranibizumab with panretinal photocoagulation among participants with proliferative diabetic retinopathy. JAMA Ophthalmol. 2017;135(6):672–3.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Figueira J, Fletcher E, Massin P, Silva R, Bandello F, Midena E, et al. Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS study). Ophthalmology. 2018;125(5):691–700.

    Article  PubMed  Google Scholar 

  46. DongNguyen Q, Brown D, Marcus D, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.

    Article  Google Scholar 

  47. Bressler S, Odia I, Glassman A, et al. Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab: DRCR.net protocol I 5-year report. Retina. 2018;38(10):1896–904.

    Article  PubMed  Google Scholar 

  48. Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2):213–6.

    Article  CAS  PubMed  Google Scholar 

  49. • Hutton DW, Stein JD, Bressler NM, et al. Cost-effectiveness of intravitreous ranibizumab compared with panretinal photocoagulation for proliferative diabetic retinopathy. JAMA Ophthalmol. 2017;135(6):576–84 This study outlines the cost analysis of the 2-year Protocol S data in comparing the use of ranibizumab vs PRP for DME.

    Article  PubMed  PubMed Central  Google Scholar 

  50. • Lin J, Chang JS, Yannuzzi NA, Smiddy WE. Cost evaluation of early vitrectomy versus panretinal photocoagulation and intravitreal ranibizumab for proliferative diabetic retinopathy. Ophthalmology. 2018;125(9):1393–400 This study suggests that the cost utility of PPV vs PRP is similar and that PPV has a more favorable cost utility as compared to ranibizumab.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The editors thank Dr. Fernando Penha for lending his expertise and reviewing this manuscript.

Financial Support

This study is supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research EPID-006-15S, NIH Center Core Grant P30EY014801, and Research to Prevent Blindness Unrestricted Grant.

Author information

Authors and Affiliations

  1. VA North Texas Health Care System, 4500 S. Lancaster Rd, Dallas, TX, 75216, USA

    Mary B. Kansora

  2. Department of Ophthalmology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA

    Mary B. Kansora

  3. Surgical Services, Miami Veterans Administration Medical Center, 1201 NW 16th Street, Miami, FL, 33125, USA

    Raquel Goldhardt

  4. Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, 900 NW 17th Street, Suite 275, Miami, FL, 33136, USA

    Raquel Goldhardt

Authors
  1. Mary B. Kansora
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raquel Goldhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raquel Goldhardt.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Retina

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kansora, M.B., Goldhardt, R. Decision Making in Proliferative Diabetic Retinopathy Treatment. Curr Ophthalmol Rep 7, 45–50 (2019). https://doi.org/10.1007/s40135-019-00198-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40135-019-00198-w

Keywords

Search

Navigation